What the Health? From KFF Health News: The Government Is Open
The Host Emmarie Huetteman KFF Health News Emmarie Huetteman, senior editor, oversees a team of Washington reporters, as well as “Bill of the Month” and “What the Health? From KFF Health News.” She previously spent more than a decade reporting on the federal government, most recently covering surprise medical bills, drug pricing reform, and other health policy […]
Merck’s heart disease win and the FDA’s new drug regulator
What does Rick Pazdur’s new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss the long-awaited trial results for the company’s oral medicine targeting […]
Eating this before breakfast and lunch can mimic Ozempic
GLP-1 drugs like Ozempic work by mimicking the GLP-1 hormone to regulate blood sugar and trigger weight loss.
Pfizer CEO vows company will be a ‘formidable competitor’ in booming weight-loss market after $10B buy
Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a “formidable competitor” after securing a $10 billion deal to acquire obesity-drug developer Metsera. “Pfizer, when it plays, plays big, and we will, as we did in COVID, as with Lipitor, as [with] Viagra, with […]
Livers of MASLD Patients End Up Less Fatty With Novel Injectable
(MedPage Today) — WASHINGTON — A large percentage of people with metabolic dysfunction-associated steatotic liver disease (MASLD) had their liver fat content normalize with an investigational dual agonist of the GLP-1 and glucagon receptors…
Patients With Colon Cancer May See Extra GLP-1 Benefits
Medications like Wegovy and Ozempic, known for managing diabetes and promoting weight loss, may also be linked to significantly lower death rates in colon cancer patients, according to a new study cited by the Independent . Researchers at UC San Diego reviewed medical records for more than 6,800 colon cancer…
Why Tracking Could Still Help on GLP-1s—Even When You’re Not Hungry
Feeling less hungry on GLP-1 medications may make tracking feel difficult. When portions shrink, cravings quiet down, and the scale moves without much effort, it’s easy to assume you have it covered. The catch is that lower appetite can also mean missed protein, too little fiber, not enough fluids, and fewer vitamins and minerals (1). […]
Pharmaceuticals, Vol. 18, Pages 1726: Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA
Pharmaceuticals, Vol. 18, Pages 1726: Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA Pharmaceuticals doi: 10.3390/ph18111726 Authors: Katarzyna Gryglewska-Wawrzak Agnieszka Kapłon-Cieślicka Agnieszka Pawlak Anna Tomaszuk-Kazberuk Paweł Rubiś Jacek Niedziela Agata Bielecka-Dąbrowa Obesity is a complex, multifactorial disease wherein the excessive accumulation of […]
Zealand hits pause on dual GLP-1/GLP-2 asset as CMO cites ‘increasingly crowded’ metabolic development scene
Zealand is pausing development on its dual GLP-1/GLP-2 agonist, known as dapiglutide, as it strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation,” the company said in an earnings announcement.
Weight-loss drugs linked to dramatically lower death rates in colon cancer patients
GLP-1 receptors – the drugs behind Ozempic and Mounjaro – could have great benefits for colon cancer patients, the study suggests